пятница, 20 июня 2008 г.

[cellular genetics] regulation of neurogenesis and epidermal growth factor receptor signaling by the insulin receptor/target of rapamycin pathway in drosophila

Vol.843-853, June 2008, Copyright 2008 doi:10.Article All Versions of this Article: 179/2/843 _most recent_ Services Google Scholar PubMed REGULATION OF NEUROGENESIS AND EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING BY THE INSULIN RECEPTOR/TARGET OF RAPAMYCIN PATHWAY IN DROSOPHILA HELEN MCNEILL, GAVIN M.AND JOSEPH M._ Samuel Lunenfeld Research Institute, Toronto, Ontario M5G 1X5, Canada and The Wolfson Centre For Age-Related Diseases, King's College, London SE1 1UL, United Kingdom _ 1 _Corresponding author:_ The Wolfson Centre For Age-Related Disease, King's College London, Guy's Campus, London, SE1 1UL, United Kingdom.Joseph_matthew. Determining how growth and differentiation are coordinated is key to understanding normal development, as well as disease states such as cancer, where that control is lost.Have previously shown that growth and neuronal differentiation are coordinated by the insulin receptor/target of rapamycin (TOR) kinase (InR/TOR) pathway.We show that the control of growth and differentiation diverge downstream of TOR.Regulates growth by controlling the activity of S6 kinase (S6K) and eIF4E.Of _s6k_ delays differentiation, and is epistatic to the loss of _tsc2_, indicating that S6K acts downstream or in parallel to TOR in differentiation as in growth.Loss of _eIF4E_ inhibits growth but does not affect the timing of differentiation.Also show, for the first time in Drosophila, that there is crosstalk between the InR/TOR pathway and epidermal growth factor receptor (EGFR) signaling.Signaling regulates the expression of several EGFR pathwayponents including _pointedP2_ (_pntP2_).Addition, reduction of EGFR signaling levels phenocopies inhibition of the InR/TOR pathway in the regulation of differentiation.
Read more CDC: Measles cases in US top 70, highest in 6 years (AP)
Get more [biology of neoplasia] selective estrogen-receptor modulators and antihormonal resistance in breast cancer